Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Tax Provisions (2024 - 2025)

BridgeBio Pharma (BBIO) has disclosed Tax Provisions for 2 consecutive years, with -$120000.0 as the latest value for Q4 2025.

  • Quarterly Tax Provisions fell 110.41% to -$120000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at $435000.0 for FY2025, 62.27% down from the prior year.
  • Tax Provisions hit -$120000.0 in Q4 2025 for BridgeBio Pharma, up from -$1.5 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $2.1 million in Q2 2025 to a low of -$1.5 million in Q3 2025.